Partners &
Medical professionals

A wide body of evidence substantiates the efficacy of InsuJet™.

Take a deeper dive into the research that speaks to its benefits.

The reports are in. Read the clinical evidence.

Adult, overweight or obese (BMI ≥25 and ≤40 kg/m2) patients with type 1 diabetes (n=10) or insulin-treated type 2 diabetes (n=10) were enrolled in a randomized, controlled, crossover study. On two separate occasions, patients were instructed to reduce insulin dose(s) to achieve marked hyperglycaemia (18–23 mmol/l). Subsequently, insulin aspart was administered either by jet injection or by conventional pen, in a dose based on estimated individual insulin sensitivity. Pharmacodynamic and pharmacokinetic profiles were derived from plasma glucose and insulin levels, measured for 6 h after injection.

It was concluded that administration of rapid-acting insulin by jet injection results in faster correction ofmarked hyperglycaemia in overweight or obese patients with insulin-requiring diabetes.

Jet injectors allow needle-free insulin delivery. The study objective was to compare the tolerability and device preference of subcutaneous insulin aspart delivery by jet injector with pen injection in an open-label, randomized, crossover pilot study.

In this small pilot study, the devices were similar in glucose excursion in the area under the glucose concentration–time curve corrected for baseline glucose level and in insulin absorption. Devices were similar for participant preference and relative injection pain.

It was concluded that subcutaneous jet injection of aspart insulin was well tolerated.

Clamp studies have shown that the absorption and action of rapid-acting insulin are faster with injection by a jet injector than with administration by conventional pen. To determine whether these pharmacokinetic changes also exist in patients with diabetes and benefit postprandial glucose control, a comparison was made of the pharmacologic profiles of insulin administration by jet injection versus conventional insulin pen after a standardized meal in patients with type 1 or type 2 diabetes.

Results showed that insulin administration by jet injection resulted in shorter time until peak plasma insulin level and reduced hyperglycemic burden during the first hour compared with conventional ad-ministration. Jet injection did not, however, significantly reduce the hyperglycemic burden during the 5-h period thereafter. There was no indication that the jet injector performed differently in patients with type 1 and type 2 diabetes.

It was concluded that the considerably more rapid insulin absorption after administration by jet injector translated to a significant if modest decrease in postprandial hyperglycemia in patients with type 1 and type 2 diabetes. The improved early postprandial glucose control may specifically benefit patients who have difficulty in limiting postprandial glucose excursions.

In a euglycaemic glucose clamp study with healthy volunteers it was showed that using jet injectors, rather than conventional pens, significantly improved the time-action profiles of rapid-acting insulin analogs. Here, it was investigated whether such profiles were modified by body mass index (BMI) and related weight parameters by comparing insulin administration by jet injection to that by conventional pen in subgroups defined by BMI, waist-to-hip ratio, waist circumference and insulin dose.

After conventional administration, times to peak insulin levels (T-INSmax) occurred 31.1 [95% confidence interval (CI) 13.7–48.5] minutes later and time to maximum glucose requirement (T-GIRmax) 56.9 (95%CI 26.6–87.3) minutes later in more obese (BMI > 23.6 kg/m2) than in lean subjects (BMI < 23.6 kg/m2). In contrast, T-INSmax and T-GIRmax were similar in subjects with high and low BMI, when insulin was administered by jet injection.

It was concluded that using jet injection for insulin administration may especially benefit subjects with higher body weight.

InsuJet™ 's clinical trials, performed by a renowned Dutch academic hospital, were performed to com-pare the pharmacologic profile of administration of insulin aspart by jet injection to that by convention-al insulin pen.

Results showed that the time to maximal GIR was significantly shorter when insulin was injected with the jet injector, compared with conventional pen administration. The time to peak insulin concentration was similarly reduced and peak insulin concentrations were increased. Jet injector insulin administration reduced the time to 50% glucose disposal. No differences were measured in maximal GIR, total insulin absorption, or total insulin action between the two devices.

Conclusions were drawn that administration of insulin aspart by jet injection enhances insulin absorption and reduces the duration of glucose-lowering action. This profile resembles more closely the pat-tern of endogenous insulin secretion and may help to achieve better meal insulin coverage and correction of postprandial glucose excursions.

Key information about InsuJet™ for medical professionals

ISO

Click the image to download the ISO 13485: 2016, QMS Certificate

CE

Click the image to download the CE/ EC 0459 Certificate.

40+

InsuJet™ Countries

3

Global InsuJet™ Offices

25+

InsuJet™ Partners

Country certificates

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Please click the image to see the pdf of our local certificate for trading medical equipment.

Needle-free insulin administration

InsuJet™ works by pushing liquid under high pressure through a tiny orifice in the front of a nozzle, the liquid gets enough speed and pressure to pass through the skin. Once in the subcutaneous tissue, the liquid follows the path of least resistance, which ensures good distribution of the liquid.

One size fits all

Or better, one InsuJet™ is suitable for any size, gender, or age of subject. InsuJet™ may especially benefit people with a higher Body Mass Index (BMI).

A team effort

Contact us to arrange an appointment with your regional manager or distributor to demonstrate or further explain the InsuJet™ system.

E-Commerce distribution partners

InsuJet™ works with 10XCREW our distribution partner to fulfil orders shipped to Asia/Pacific, EU, and MENA regions. For more information about 10XCREW please visit www.10xcrew.com

Information on InsuJet™ Clarification of intended use, InsuJet™ Intended patient populations, Warnings, InsuJet™ Contraindications, InsuJet™ Administration site selection guide, InsuJet™ Safety information, and Possible InsuJet™ Side effects.

Information on the clinical data of the InsuJet™, clinical benefits, clinical investigation summary.

Information on the InsuJet™ market history, InsuJet™ user survey feedback and key findings, and InsuJet™ PMS follow-up. 

Information on InsuJet™ design history, and InsuJet™ Usability testing.

Information on the InsuJet™ compatibility, InsuJet™ Adaptors, and Insulin compatibility data.

Information on the cost of insulin therapy, and sharps waste management.

Get started with the
needle-free insulin
injection system.

ISO 13485

CE CERTIFIED

TGA

HEALTH CANADA

NHS COVERED

Disclaimers:

01. Types d'insuline compatibles : humaine et animale ; Insulines à action rapide (bolus); analogues d'insuline à action rapide ; Insuline Humaine Régulière ; Insulines basales ; Action intermédiaire, généralement : NPH/ Isophane ; Action prolongée, couramment : Glargine, détémir, degludec ; Prémélanges (ex. 30/70).

    02. Dans une enquête auprès des utilisateurs, 78 % des personnes interrogées ont répondu qu'elles recommanderaient InsuJet™ à d'autres.

    03. Dans une enquête auprès des utilisateurs, 40 % des personnes interrogées ont répondu avoir remarqué qu'elles consommaient moins d'insuline.

    04. L'injection par jet sans aiguille d'insuline à action rapide améliore le contrôle précoce de la glycémie postprandiale chez les patients atteints de diabète. Soins du diabète, octobre 2013.

    05. Indice de masse corporelle et efficacité de l'injection par jet sans aiguille pour l'administration d'analogues d'insuline à action rapide, une analyse post hoc. Diabète, obésité et métabolisme, juillet 2012.

    06. Amélioration du profil pharmacocinétique et pharmacodynamique de l'insuline à action rapide à l'aide de la technologie d'injection par jet sans aiguille. Soins du diabète, août 2011

    07. Une étude pilote pour examiner la tolérance et la préférence de dispositif dans le diabète de type 1 de l'insuline séparée administrée par InsuJet™ par rapport à l'injection sous-cutanée. Technologie et thérapeutique du diabète, 2014.

    08. Voir Medical Deck Cost Analysis - North America, 2022 disponible sur la page Partner.

    09. Calculé à 4 injections par jour avec une aiguille hypodermique. 4 injections par jour, tous les jours de l'année, cela représente 1 460 aiguilles économisées par an.

    *. L'InsuJet™ est calibré pour les insulines U-100

    **. Le calibre d'aiguille 26-27 est couramment utilisé pour les injections sous-cutanées et mesure environ 0,40 à 0,45 mm de diamètre. L'orifice de la buse InsuJet™ mesure environ 0,15 mm de diamètre, ce qui est beaucoup plus petit que les calibres d'aiguille conventionnels utilisés pour les injections sous-cutanées d'insuline.

    ***. https://pubmed.ncbi.nlm.nih.gov PMID :18820853